Company intelligence / Profile preview

GliaMed, Inc.

California, United States

Ownership: Private
Development stage: Other

Overview

GliaMed has demonstrated pre-clinical data on tissue regeneration through in vivo induction and recruitment of stem cells, particularly for wound healing. Historical Phase 2 trials for GM-1485 (GPI-1485) in prostatectomy recovery and Parkinson's disease were completed by Eisai but discontinued.

Therapeutic areas: OncologyNeurologyRheumatologyDermatology
Modalities: Small molecule
Industry: Biotech

Drug pipeline

1 asset

GT 715

Preclinical

Partnerships

Eisai Co., Ltd. (historical)

Beyond the preview

Go deeper on GliaMed, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GliaMed, Inc..

Explore the full profile